Jump to content

Brompheniramine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 83d40m (talk | contribs) at 00:27, 15 December 2020 (antihistamine brand dimetane : dimetapp). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Brompheniramine
Clinical data
Trade namesBromfed, Dimetapp, Bromfenex, and others
AHFS/Drugs.comMonograph
MedlinePlusa682545
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • AU: S4 / S3 / S2
  • US: Rx-only / OTC
  • Unscheduled, OTC
Pharmacokinetic data
MetabolismHepatic
Elimination half-life24.9 ± 9.3 hours[1]
ExcretionUrine
Identifiers
  • (R/S)-3-(4-Bromophenyl)-N,N-dimethyl-3-pyridin-2-yl-propan-1-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.001.507 Edit this at Wikidata
Chemical and physical data
FormulaC16H19BrN2
Molar mass319.246 g·mol−1
3D model (JSmol)
  • Brc1ccc(cc1)C(c2ncccc2)CCN(C)C
  • InChI=1S/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3 checkY
  • Key:ZDIGNSYAACHWNL-UHFFFAOYSA-N checkY
  (verify)

Brompheniramine, sold under the brand name Dimetapp among others, is an antihistamine drug of the propylamine (alkylamine) class.

It is indicated for the treatment of the symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing.

It is a first-generation antihistamine and one of the drugs of highest anticholinergic activity.

It was patented in 1948 and came into medical use in 1955.[2]

Side effects

Brompheniramine's effects on the cholinergic system may include side-effects such as drowsiness, sedation, dry mouth, dry throat, blurred vision, and increased heart rate. It is listed as one of the drugs of highest anticholinergic activity in a study of anticholinergenic burden, including long-term cognitive impairment.[3]

Pharmacology

Brompheniramine works by acting as an antagonist of histamine H1 receptors. It also functions as a moderately effective anticholinergic agent, and is likely an antimuscarinic agent similar to other common antihistamines such as diphenhydramine.

Brompheniramine is metabolised by cytochrome P450s.

The halogenated alkylamine antihistamines all exhibit optic isomerism and brompheniramine products contain racaemic brompheniramine maleate whereas dexbrompheniramine (Drixoral) is the dextrorotary (right-handed) stereoisomer.[citation needed]

Chemistry

Brompheniramine is part of a series of antihistamines including pheniramine (Naphcon) and its halogenated derivatives and others including fluorpheniramine, chlorpheniramine, dexchlorpheniramine (Polaramine), triprolidine (Actifed), and iodopheniramine. The halogenated alkylamine antihistamines all exhibit optical isomerism and brompheniramine products contain racemic brompheniramine maleate whereas dexbrompheniramine (Drixoral) is the dextrorotary (right-handed) stereoisomer.

Brompheniramine is an analog of chlorpheniramine. The only difference is that the chlorine atom in the benzene ring is replaced with a bromine atom. It is also synthesized in an analogous manner.[4][5]

History

Based on this[which?] knowledge, Arvid Carlsson and his colleagues, working at the Swedish company Astra AB, were able to derive the first marketed selective serotonin reuptake inhibitor, zimelidine, from brompheniramine.[6]

Names

Brand names include Bromfed, Dimetapp, Bromfenex, Dimetane, BPN, Lodrane. It is commonly marketed as its salt brompheniramine maleate.

See also

References

  1. ^ Simons FE, Frith EM, Simons KJ (December 1982). "The pharmacokinetics and antihistaminic effects of brompheniramine". The Journal of Allergy and Clinical Immunology. 70 (6): 458–64. doi:10.1016/0091-6749(82)90009-4. PMID 6128358.
  2. ^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 546. ISBN 9783527607495.
  3. ^ Salahudeen MJ; Duffull SB; Nishtala PS; et al. (2015-03-25). "Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review". BMC Geriatrics. 15 (31): 31. doi:10.1186/s12877-015-0029-9. PMC 4377853. PMID 25879993.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  4. ^ L.A. Walter, U.S. patent 3,061,517 (1962)
  5. ^ L.A. Walter, U.S. patent 3,030,371 (1962)
  6. ^ Barondes, Samuel H. (2003). Better Than Prozac. New York: Oxford University Press. pp. 39–40. ISBN 0-19-515130-5.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Brompheniramine&oldid=994297576"